Explore our strategy and projects
to learn about the future of our company
Results FY 2024 (€/MLN)
1,185
Revenues
394
Adjusted EBITDA
236
Adjusted net profit
241
Free cash flow
Stock price
Discover morePress releases
31/10/25 - 10:12
Diasorin receives 510(k) clearance for Simplexa COVID-19, Flu A/B & RSV Direct kit on the LIAISON MDX from the U.S. Food and Drug Administration
22/10/25 - 7:41
Diasorin signs a supplier agreement with Quest Diagnostics for the innovative molecular multiplexing platform, LIAISON PLEX
LIAISON PLEX® System: the new multiplexing platform of the Group
Diasorin's LIAISON PLEX® System and Respiratory Flex Assay Revolutionize Diagnostics with Flexibility and have Earned FDA Clearance.
Keep
in touch
Sign up for our investor alerts
and stay informed
on the latest developments